目的评价固尔苏预防早产儿呼吸窘迫综合征(NRDS)的临床疗效及安全性。方法将48例胎龄27～32周、体重900～1500g的早产儿随机分为两组,预防组生后2h内气管内滴入固尔苏,对照组不用固尔苏,两组患儿均给予相同的综合治疗,比较两组发生NRDS的比例、需要呼吸机治疗的比例、开始上机时间、机械通气的时间及胸片改变的严重程度。结果(1)预防组发生NRDS的比例、需要呼吸机治疗的例数及呼吸机辅助通气时间较对照组少,二者比较有统计学意义(P<0.05);(2)两组发生NRDS的患儿胸片改变预防组比对照组程度轻。结论早产儿生后预防性应用固尔苏可以降低NRDS发生率及减轻发病程度,固尔苏使用是安全的。 Objective To evaluate the clinical efficacy and safety of Guerrezu in preventing premature infants with respiratory distress syndrome (NRDS). Methods Forty-eight preterm infants with gestational age ranging from 27 to 32 weeks and weighing from 900 to 1500 g were randomly divided into two groups. Given the same combination therapy, the proportion of ventilator-treated patients, the time to start the machine, the duration of mechanical ventilation, and the severity of the change in chest radiographs were compared between the two groups in terms of NRDS. Results (1) The proportion of NRDS in the prevention group was lower than that in the control group (P <0.05); (2) The number of NRDS in the prevention group was lower than that in the control group Children with chest change prevention group lighter than the control group. CONCLUSIONS: Preventive use of cefoxitin in preterm infants can reduce the incidence of NRDS and reduce the incidence of the disease. The use of cefazolin is safe.